HRP980096A2
(en)
|
1997-02-26 |
1998-12-31 |
Glaxo Group Ltd |
Reverse hydroxamate derivatives as matrix metalloprotease inhibitors, metalloprotease inhibitors, and tnf alpha inhibitors
|
ZA988967B
(en)
|
1997-10-03 |
2000-04-03 |
Du Pont Pharm Co |
Lactam metalloprotease inhibitors.
|
SE9704544D0
(sv)
|
1997-12-05 |
1997-12-05 |
Astra Pharma Prod |
Novel compounds
|
SE9704546D0
(sv)
|
1997-12-05 |
1997-12-05 |
Astra Pharma Prod |
Novel compounds
|
SE9704545D0
(sv)
|
1997-12-05 |
1997-12-05 |
Astra Pharma Prod |
Novel compounds
|
EP1087937A1
(en)
|
1998-06-17 |
2001-04-04 |
Du Pont Pharmaceuticals Company |
Cyclic hydroxamic acids as metalloproteinase inhibitors
|
US6239151B1
(en)
|
1998-06-26 |
2001-05-29 |
Hoffmann-La Roche Inc. |
Compounds as inhibitor of tumor necrosis factor alpha release
|
UA59453C2
(uk)
|
1998-08-12 |
2003-09-15 |
Пфайзер Продактс Інк. |
Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
|
US20040122011A1
(en)
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
US6225311B1
(en)
|
1999-01-27 |
2001-05-01 |
American Cyanamid Company |
Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
|
BR0009651A
(pt)
|
1999-04-09 |
2002-01-08 |
Astrazeneca Ab |
Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
|
SE9901875D0
(sv)
|
1999-05-25 |
1999-05-25 |
Astra Pharma Prod |
Novel compounds
|
SE9904505D0
(sv)
|
1999-12-09 |
1999-12-09 |
Astra Pharma Prod |
Novel compounds
|
TWI258462B
(en)
|
1999-12-17 |
2006-07-21 |
Astrazeneca Ab |
Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
|
SE9904652D0
(sv)
|
1999-12-17 |
1999-12-17 |
Astra Pharma Prod |
Novel Compounds
|
SE9904738D0
(sv)
|
1999-12-22 |
1999-12-22 |
Astra Pharma Prod |
Novel compounds
|
GB0013737D0
(en)
|
2000-06-07 |
2000-07-26 |
Astrazeneca Ab |
Novel compounds
|
WO2002018326A1
(fr)
|
2000-08-31 |
2002-03-07 |
Wakunaga Pharmaceutical Co., Ltd. |
Nouveaux derives d'acide propenohydroxamique
|
WO2002096426A1
(en)
|
2001-05-25 |
2002-12-05 |
Bristol-Myers Squibb Company |
Hydantion derivatives as inhibitors of matrix metalloproteinases
|
WO2003016248A2
(en)
|
2001-08-17 |
2003-02-27 |
Bristol-Myers Squibb Company Patent Department |
Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
|
WO2003024899A2
(en)
|
2001-09-17 |
2003-03-27 |
Bristol-Myers Squibb Company |
CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
|
WO2003031431A1
(en)
|
2001-10-09 |
2003-04-17 |
Bristol-Myers Squibb Company |
Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
|
US6884806B2
(en)
|
2001-10-17 |
2005-04-26 |
Bristol-Myers Squibb Company |
Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
|
WO2003040103A1
(en)
|
2001-11-02 |
2003-05-15 |
Bristol-Myers Squibb Company |
β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
|
PA8557501A1
(es)
|
2001-11-12 |
2003-06-30 |
Pfizer Prod Inc |
Benzamida, heteroarilamida y amidas inversas
|
WO2003042190A1
(en)
|
2001-11-12 |
2003-05-22 |
Pfizer Products Inc. |
N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
|
SE0103836D0
(sv)
|
2001-11-16 |
2001-11-16 |
Astrazeneca Ab |
Novel compounds
|
WO2003047515A2
(en)
|
2001-11-30 |
2003-06-12 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
P2x7 receptor antagonists
|
US7294624B2
(en)
|
2001-12-20 |
2007-11-13 |
Bristol Myers Squibb Company |
Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
|
CN1617725A
(zh)
|
2001-12-21 |
2005-05-18 |
王者制药研究发展有限公司 |
酪氨酰衍生物及其作为p2x7受体调节剂的用途
|
US7101883B2
(en)
|
2002-03-18 |
2006-09-05 |
Bristol-Myers Squibb Company |
Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases
|
SE0200920D0
(sv)
|
2002-03-25 |
2002-03-25 |
Astrazeneca Ab |
Novel compounds
|
GB0216379D0
(en)
|
2002-07-13 |
2002-08-21 |
Astrazeneca Ab |
Compounds
|
AU2003261319A1
(en)
|
2002-08-01 |
2004-02-23 |
Bristol-Myers Squibb Company |
Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
|
WO2004033632A2
(en)
|
2002-10-04 |
2004-04-22 |
Bristol-Myers Squibb Company |
Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
|
EP1558581A4
(en)
|
2002-10-07 |
2007-07-25 |
Bristol Myers Squibb Co |
DERIVATIVES OF TRIAZOLONE AND TRIAZOLETHIONE
|
AU2003301903A1
(en)
|
2002-11-06 |
2004-06-03 |
Bristol-Myers Squibb Company |
Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
|
BR0317844A
(pt)
|
2002-12-31 |
2005-12-06 |
Pfizer Prod Inc |
Inibidores de benzamida do receptor p2x7
|
PA8591801A1
(es)
|
2002-12-31 |
2004-07-26 |
Pfizer Prod Inc |
Inhibidores benzamidicos del receptor p2x7.
|
SE0300480D0
(sv)
|
2003-02-21 |
2003-02-21 |
Astrazeneca Ab |
Novel compounds
|
ES2396565T3
(es)
|
2003-05-12 |
2013-02-22 |
Pah Usa 15 Llc |
Inhibidores benzamida del receptor P2X7
|
GB0312609D0
(en)
|
2003-06-02 |
2003-07-09 |
Astrazeneca Ab |
Novel compounds
|
US7132432B2
(en)
|
2003-06-05 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
|
GB0324498D0
(en)
|
2003-07-21 |
2003-11-26 |
Aventis Pharma Inc |
Heterocyclic compounds as P2X7 ion channel blockers
|
SE0302139D0
(sv)
|
2003-07-28 |
2003-07-28 |
Astrazeneca Ab |
Novel compounds
|
SE0302192D0
(sv)
|
2003-08-08 |
2003-08-08 |
Astrazeneca Ab |
Novel compounds
|
WO2005019182A1
(en)
|
2003-08-20 |
2005-03-03 |
Bayer Healthcare Ag |
Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists
|
WO2005039590A1
(en)
|
2003-10-21 |
2005-05-06 |
Inspire Pharmaceuticals, Inc. |
Non-nucleotide compositions and method for treating pain
|
MXPA06012595A
(es)
|
2004-04-29 |
2007-05-09 |
Abbott Lab |
Analogos de amino-tetrazoles y metodos de uso.
|
MXPA06015273A
(es)
|
2004-06-29 |
2007-03-15 |
Pfizer Prod Inc |
Procedimiento para preparar derivados de 5-[4-(2-hidroxi -etil)-3, 5-dioxo-4, 5-dihidro-3h-[1, 2, 4]-triazin -2-il]-benzamida con actividad inhibidora de p2x7 mediante reaccion del derivado no sustituido en posicion 4 de la triazina con un oxirano en
|
CN1980902A
(zh)
|
2004-06-29 |
2007-06-13 |
辉瑞产品有限公司 |
通过对羟基保护前体去保护而制备5-4-(2-羟基-丙基)-3,5-二氧代-4,5-二氢-3h-[1,2,4]三嗪-2-基-苯甲酰胺衍生物的方法
|
US7241776B2
(en)
|
2004-08-02 |
2007-07-10 |
Abbott Laboratories |
Cyanoamidine P2X7 antagonists for the treatment of pain
|
SA05260265A
(ar)
|
2004-08-30 |
2005-12-03 |
استرازينيكا ايه بي |
مركبات جديدة
|
SE0402925D0
(sv)
|
2004-11-30 |
2004-11-30 |
Astrazeneca Ab |
Novel Compounds
|
DE602005026703D1
(de)
|
2004-12-24 |
2011-04-14 |
Astrazeneca Ab |
Amidderivate
|
EP1844003A4
(en)
|
2005-01-27 |
2010-09-22 |
Astrazeneca Ab |
NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
|
US20060211739A1
(en)
|
2005-02-08 |
2006-09-21 |
Arturo Perez-Medrano |
Use of selective P2X7 receptor antagonists
|
US7402596B2
(en)
|
2005-03-24 |
2008-07-22 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
WO2006110516A1
(en)
|
2005-04-11 |
2006-10-19 |
Abbott Laboratories |
Acylhydrazide p2x7 antagonists and uses thereof
|
WO2006136004A1
(en)
|
2005-05-05 |
2006-12-28 |
Medicure International Inc. |
Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
|
WO2007016597A2
(en)
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
WO2007025366A1
(en)
|
2005-08-29 |
2007-03-08 |
Irma Bernatchez-Lemaire |
Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents
|
WO2007028022A2
(en)
|
2005-09-01 |
2007-03-08 |
Renovis, Inc. |
Novel compounds as p2x7 modulators and uses thereof
|
JP2009514864A
(ja)
|
2005-11-07 |
2009-04-09 |
アボット・ラボラトリーズ |
P2x7受容体拮抗薬および使用方法
|
EP1963275A2
(en)
|
2005-11-09 |
2008-09-03 |
Abbott Laboratories |
P2x7 receptor antagonists and uses thereof
|
US20100298285A1
(en)
|
2006-03-16 |
2010-11-25 |
Kelly Michael G |
Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
|
EP2001474B1
(en)
|
2006-03-16 |
2016-03-09 |
Second Genome, Inc. |
Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
|
WO2007109154A2
(en)
|
2006-03-16 |
2007-09-27 |
Renovis, Inc. |
Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
|
TWI464148B
(zh)
|
2006-03-16 |
2014-12-11 |
Evotec Us Inc |
作為p2x7調節劑之雙環雜芳基化合物與其用途
|
ES2596532T3
(es)
|
2006-03-16 |
2017-01-10 |
Second Genome, Inc. |
Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
|
WO2007109201A2
(en)
|
2006-03-16 |
2007-09-27 |
Renovis, Inc. |
Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
|
JP2009539795A
(ja)
|
2006-06-06 |
2009-11-19 |
グラクソ グループ リミテッド |
疼痛、炎症および神経変性の治療のためのp2x7アンタゴニストとしてのn−(フェニルメチル)−2−(1h−ピラゾール−4−イル)アセトアミド誘導体
|
GB0611154D0
(en)
|
2006-06-06 |
2006-07-19 |
Glaxo Group Ltd |
Novel receptor antagonists and their methods of use
|
US20080076924A1
(en)
|
2006-06-30 |
2008-03-27 |
Patrick Betschmann |
Piperazines as P2X7 antagonists
|
EA016076B1
(ru)
|
2006-07-06 |
2012-01-30 |
Глэксо Груп Лимитед |
Замещенные n-фенилметил-5-оксопролин-2-амиды в качестве антагонистов р2х7-рецептора и способы их применения
|
US20080058309A1
(en)
|
2006-07-27 |
2008-03-06 |
Astrazeneca Ab |
Novel Compounds 171
|
BRPI0809930A2
(pt)
|
2007-04-03 |
2014-10-07 |
Glaxo Group Ltd |
Derivados de carboxamida imidazolidina como moduladores de p2x7
|
MX2009010523A
(es)
|
2007-04-10 |
2009-12-15 |
Lundbeck & Co As H |
Análogos de amidas heteroarílicas como antagonistas de p2x7.
|
JP2010523623A
(ja)
|
2007-04-11 |
2010-07-15 |
グラクソ グループ リミテッド |
P2x7調節因子としてのピラゾール誘導体
|
US20110046137A1
(en)
|
2007-05-10 |
2011-02-24 |
Glaxo Group Limited |
Pyrazole Derivatives as P2X7 Modulators
|
WO2009019503A2
(en)
|
2007-08-03 |
2009-02-12 |
Astrazeneca Ab |
P2x7 antagonists for use in the treatment of mood disorders
|
AU2008286946B2
(en)
*
|
2007-08-10 |
2013-11-21 |
H. Lundbeck A/S |
Heteroaryl amide analogues
|
JP2011500767A
(ja)
|
2007-10-26 |
2011-01-06 |
グラクソ グループ リミテッド |
P2x7モジュレータとしての4−ベンゾイル−1−置換ピペラジン−2−オン誘導体
|
PE20091036A1
(es)
|
2007-11-30 |
2009-08-15 |
Astrazeneca Ab |
Derivado de quinolina como antagonista del receptor p2x7
|
US20100292295A1
(en)
|
2007-12-18 |
2010-11-18 |
Glaxo Group Limited |
5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
|
ES2357682T3
(es)
|
2008-03-25 |
2011-04-28 |
Affectis Pharmaceuticals Ag |
Antagonistas de p2x7r novedosos y su utilización.
|
US8431704B2
(en)
|
2008-04-22 |
2013-04-30 |
Janssen Pharmaceutica Nv |
Quinoline or isoquinoline substituted P2X7 antagonists
|
MX2011010810A
(es)
|
2009-04-14 |
2012-01-12 |
Affectis Pharmaceuticals Ag |
Nuevos antagonistas de p2x7r y su uso.
|
GB0907425D0
(en)
|
2009-04-29 |
2009-06-10 |
Glaxo Group Ltd |
Compounds
|